BDA-366 is a small-molecule antagonist of the Bcl2-BH4 domain, used as an anticancer agent by inducing conformational changes in BCL2, thereby converting it into a pro-death protein and triggering apoptosis in multiple myeloma and lung cancer cells; it specifically targets Bcl2 without binding to other Bcl2 family members such as Bcl-XL, Mcl-1, or Bfl-1/A1; it inhibits tumor growth in vivo in models of human multiple myeloma and lung cancer with minimal toxicity to normal hematopoietic cells or body weight; it induces Bax-dependent apoptotic cell death and promotes calcium release by disrupting the Bcl2/IP3R interaction; it effectively suppresses lung cancer progression in animal models without reducing platelet counts.